相关实验视频

Updated: Jun 17, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

对患有"低风险"疾病的患者进行乳腺癌分期:它们都是一样的吗?

Tori C Nierenberg¹, Samantha M Thomas², Ellery H Reason¹

¹Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.

|February 14, 2026

概括

一个低的型复发率 (RS) 仅仅不能保证乳腺癌患者的良好生存. 病理预后阶段 (PPS) 对于准确的预后至关重要,即使 RS 较低.

科学领域:

在瘤学瘤学.
基因组学就是基因组学.
临床试验临床试验

背景情况:

乳腺癌的分期结合了解剖学和生物学因素.
一个低的型复发得分 (RS < 11) 通常表明有利的生存率.
仅仅低RS的预后价值对于下降到病理预后阶段 (PPS) 的IA是不确定的.

研究的目的:

评估低型复发评分 (RS) 是否在预后上相当于病理预后阶段 (PPS) IA.
确定病理预后阶段对低RS患者的存活率的影响.

主要方法:

对231,031名荷尔蒙受体阳性,HER2阴性侵袭性乳腺癌患者 (2010-2018) 的分析.
排除接受新辅助疗法或缺乏RS数据的患者.
卡普兰-梅尔和调整后的考克斯模型用于估计不同PPS组的整体存活率 (OS).

主要成果:

在RS < 11的患者中,随着病理预后阶段 (PPS IB,IIA,IIB) 更高,整体存活率下降.
在RS 11-17组中,90.8%是PPS IA,但生存率因阶段而异.
经过调整后的分析证实,在低RS组中,在不同阶段之间存在持续的OS差异.

结论:

病理预后阶段显著影响存活率,即使在型复发得分低的患者中 (RS <11).
仅仅一个低的RS就不足以自动降级到PPS IA.
解剖学和其他非基因组因素仍然对准确的乳腺癌预后至关重要.

关键词:

乳腺癌乳腺癌乳腺癌基因组测试是一种基因组测试.在类型上,型是型.预后预后预后阶段化阶段化

更多相关视频

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery

Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery

Published on: April 3, 2026

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...